Guardant Health (NASDAQ:GH) Price Target Raised to $185.00 at Morgan Stanley

Guardant Health (NASDAQ:GH) had its price objective lifted by stock analysts at Morgan Stanley from $175.00 to $185.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Morgan Stanley’s price target indicates a potential upside of 16.48% from the stock’s current price.

GH has been the subject of several other reports. Evercore reiterated an “outperform” rating and set a $200.00 target price on shares of Guardant Health in a research report on Monday, July 6th. Mizuho increased their price target on shares of Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday. Barclays raised their price objective on shares of Guardant Health from $150.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday. Sanford C. Bernstein lifted their price objective on shares of Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, July 2nd. Finally, Canaccord Genuity Group upped their target price on shares of Guardant Health from $135.00 to $205.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $180.27.

Guardant Health Trading Down 2.0%

Shares of GH opened at $158.83 on Tuesday. Guardant Health has a 12-month low of $41.19 and a 12-month high of $176.58. The company has a market cap of $21.31 billion, a PE ratio of -45.51 and a beta of 1.60. The stock has a 50-day moving average price of $144.24 and a 200-day moving average price of $113.78.

Insider Buying and Selling

In other Guardant Health news, CFO Michael Brian Bell sold 2,000 shares of Guardant Health stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $128.62, for a total transaction of $257,240.00. Following the transaction, the chief financial officer directly owned 47,509 shares of the company’s stock, valued at approximately $6,110,607.58. This trade represents a 4.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Myrtle S. Potter sold 1,556 shares of Guardant Health stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $131.16, for a total transaction of $204,084.96. Following the transaction, the director directly owned 20,971 shares in the company, valued at $2,750,556.36. This trade represents a 6.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 708,565 shares of company stock worth $90,556,597 over the last ninety days. Corporate insiders own 5.60% of the company’s stock.

Hedge Funds Weigh In On Guardant Health

Several institutional investors and hedge funds have recently made changes to their positions in GH. V Square Quantitative Management LLC purchased a new position in Guardant Health in the 4th quarter worth $27,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Guardant Health during the fourth quarter valued at about $31,000. Elyxium Wealth LLC bought a new position in shares of Guardant Health during the fourth quarter valued at about $35,000. Parallel Advisors LLC increased its holdings in shares of Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after buying an additional 219 shares during the period. Finally, EFG International AG purchased a new position in shares of Guardant Health in the fourth quarter worth about $41,000. Institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.